People

Ranking and references

Per is ranked as a Leading Individual by Legal 500 in the field of Life science, where he has been described as “incredibly approachable, responsive and very talented”.

Per Hedman

Partner

Per is head of Cirio’s Life Science, Healthcare & Food group and is recognized as a leading lawyer in the life science field. Per regularly advises clients in transactional matters as well as complex regulatory issues that arise in respect of life science, healthcare and food.

Per has extensive experience advising clients in connection with Swedish and cross-border M&A and VC investments particularly with regard to life science, healthcare and food.

Per regularly advises Swedish and foreign clients on complex regulatory and market access matters in his areas of expertise, and his command of life science issues cover both medical devices and pharma.

In addition, Per has significant experience in supporting clients in complex contractual matters whether it be of an operational nature (such as capex investment, supply of raw materials, manufacturing, and distribution) or regarding R&D. Per’s work in this regard is primarily focused in the life science, food, and forestry sectors.

Examples of assignments

  • Represented 10x Genomics, Inc., a life science technology company providing solutions for analyzing biological systems, in connection with its acquisition of the Stockholm-based company CartaNA AB.
  • Advised Elypta, a Swedish diagnostics company, in connection with its USD 21 million financing round led by Bonnier Ventures.
  • Acted for Götgatan Produktion in connection with its sale of the legendary Stockholm theater ”Göta Lejon” to Live Nation.
  • Represented Ring Holding in connection with its acquisition of the Scandinavian Burger King franchise and restaurants.
  • Acted on behalf of Hadean Ventures in connection with its investments in SAGA Diagnostics AB, Gesynta AB and Alex Therapeutics.
  • Advised Share issues in listed companies such as Boule Diagnostics AB (publ.) Intervacc AB and Annexin AB (publ.)

CV

2019 Cirio Advokatbyrå
2009 - 2018 Advokatfirman Lindahl, Partner
2000 - 2008 RydinCarlsten Advokatbyrå

Education

2002 International Law Institute, part of Georgetown Law
2000 LL.M. / Jur. kand, Uppala University
1998 - 1999 Purdue University, Krannert School of Management

Membership

2005 Admitted to the Swedish Bar Association
American Bar Association, Health Law and SIL
AIJA, International Association of Young Lawyers

Languages

Swedish
English

Ranking and references

Per is ranked as a Leading Individual by Legal 500 in the field of Life science, where he has been described as “incredibly approachable, responsive and very talented”.

Examples of assignments

  • Represented 10x Genomics, Inc., a life science technology company providing solutions for analyzing biological systems, in connection with its acquisition of the Stockholm-based company CartaNA AB.
  • Advised Elypta, a Swedish diagnostics company, in connection with its USD 21 million financing round led by Bonnier Ventures.
  • Acted for Götgatan Produktion in connection with its sale of the legendary Stockholm theater ”Göta Lejon” to Live Nation.
  • Represented Ring Holding in connection with its acquisition of the Scandinavian Burger King franchise and restaurants.
  • Acted on behalf of Hadean Ventures in connection with its investments in SAGA Diagnostics AB, Gesynta AB and Alex Therapeutics.
  • Advised Share issues in listed companies such as Boule Diagnostics AB (publ.) Intervacc AB and Annexin AB (publ.)

CV

2019 Cirio Advokatbyrå
2009 - 2018 Advokatfirman Lindahl, Partner
2000 - 2008 RydinCarlsten Advokatbyrå

Education

2002 International Law Institute, part of Georgetown Law
2000 LL.M. / Jur. kand, Uppala University
1998 - 1999 Purdue University, Krannert School of Management

Membership

2005 Admitted to the Swedish Bar Association
American Bar Association, Health Law and SIL
AIJA, International Association of Young Lawyers

Languages

Swedish
English

Related news

Cirio advises Annexin Pharmaceuticals AB (publ) in connection with its rights issue

Cirio advises Annexin Pharmaceuticals AB (publ) (”Annexin”) in connection with its rights issue of shares. The rights issue is subject…

  • Equity Capital Markets and Public M&A
  • Life Sciences
  • Life Science, Healthcare & Food

Cirio advises Annexin Pharmaceuticals AB (publ) in connection with its fully secured rights issue

Cirio advises Annexin Pharmaceuticals AB (publ) (”Annexin”) in connection with its fully secured rights issue of shares. The rights issue…

  • Life Sciences
  • Equity Capital Markets and Public M&A

Cirio contributes to Global Legal Insights – Pricing & Reimbursement 2023

Cirio is happy to share our contribution to Global Legal Insights – Pricing & Reimbursement Sixth Edition. This chapter provides…

  • Life Science, Healthcare & Food

Cirio advises Intervacc AB (publ) in connection with a rights issue

Cirio advises Intervacc AB (publ) in connection with its fully secured rights issue of shares. The board of directors of…

  • Equity Capital Markets and Public M&A

Cirio advises Boule in connection with its fully secured preferential rights issue

Cirio acts as legal adviser to Boule Diagnostics AB (publ) in connection with its fully secured preferential rights issue of…

  • Equity Capital Markets and Public M&A
  • Life Sciences
  • Banking and Finance and DCM (Debt Capital Markets)
  • Intellectual Property
  • Life Science, Healthcare & Food

Cirio Life Science Forum del 4 – Digital hälsa

Det nyss överståndna valet har medfört flera maktskiften runt om i landet, vid en tidpunkt när digitaliseringen av vården är…

  • Life Sciences

Cirio advises Elypta on its SEK 210 million financing round

Elypta AB, a Swedish cancer diagnostics company, has successfully raised SEK 210 million in a series A financing round. The…

  • Banking and Finance and DCM (Debt Capital Markets)
  • Life Sciences
  • Mergers & Acquisitions
  • Life Science, Healthcare & Food

Cirio Life Science Forum del 3 – Om vården inför valet 2022

Erfarenheterna från den gångna pandemin och debatten om privata sjukförsäkringarna har bland annat bidragit till att vården åter är en…

  • Life Sciences

Cirio Life Science Forum del 2 – HTA och cybersäkerhet för MedTech

Kraven på hälsoekonomisk utvärdering (HTA) av medicintekniska produkter växer i takt med att nya regler tar form i Sverige, EU…

  • Life Sciences

Läkemedelsåret 2021 med utblick mot 2022

Cirio Life Science Forum: Läkemedelsåret 2021 med utblick mot 2022 Välkommen till första delen i webbinarieserien Cirio Life Science Forum….

Cirio advises Scandinavian Real Heart in connection with its list change to Nasdaq First North Growth Market

Cirio acted as legal advisor to Scandinavian Real Heart AB (publ) in connection with its list change to Nasdaq First…

  • Equity Capital Markets and Public M&A
  • Life Sciences
  • Mergers & Acquisitions
  • Life Science, Healthcare & Food

Cirio contributes to 2022’s edition of Lexology Getting The Deal Through – Life Sciences

Cirio’s Life Sciences team has contributed to year 2022’s edition of Lexology Getting The Deal Through – Life Sciences. To…

  • Life Sciences
  • Life Science, Healthcare & Food

Partnering/licensering i läkemedelsindustrin – hur går det till i praktiken?

Cirio bjuder tillsammans med Sprint Bioscience in till seminarium om partnering/licensering den 7 december 2021. Licensering och annan form av…

Cirio advises Annexin in connection with its rights issue

Cirio Advokatbyrå AB advises Annexin Pharmaceuticals AB (publ), listed on Nasdaq First North Growth Market, in connection with its rights…

  • Life Sciences
  • Life Science, Healthcare & Food

Cirio advises on Kry’s acquisition of PBM

Cirio has advised the sellers of PBM Sweden on the acquisition by Kry of all the shares in PBM. PBM…

  • Banking and Finance and DCM (Debt Capital Markets)
  • Mergers & Acquisitions
  • Life Sciences
  • Life Science, Healthcare & Food

Läkemedel – en uppdatering om rättsutvecklingen 2020 och en utblick mot 2021

Under det senaste året har rättsläget kommit att utvecklas på många punkter inom life science och vård. Den rådande pandemin…

Cirio legal advisor to Ring International Holding in its acquisition of the Burger King franchise business

Cirio has acted as local counsel advising Ring International Holding AG on Swedish legal issues in its acquisition of the…

  • Mergers & Acquisitions
  • Banking and Finance and DCM (Debt Capital Markets)

Cirio legal advisor to 10x Genomics in connection with its acquisition of CartaNA

Cirio advised 10x Genomics, a market leader in single-cell analysis technology, in connection with its acquisition of the Stockholm-based company…

  • Mergers & Acquisitions
  • Life Sciences
  • Equity Capital Markets and Public M&A

Cirio advices Hadean Ventures in one of the largest private biotech investments in the Nordics this year

Gesynta Pharma AB, a clinical-stage life company developing first-in-class therapeutics for chronic inflammatory conditions such as systemic sclerosis, has successfully…

  • Life Sciences
  • Mergers & Acquisitions
  • Life Science, Healthcare & Food

Cirio advises Intervacc on private placement of SEK 147 million

Cirio has advised Intervacc AB (publ) in connection with its private placement of 6.5 million shares directed towards Swedish and…

Cirio advises Scandinavian Real Heart on a rights issue

Cirio has advised Scandinavian Real Heart AB (publ) (“Realheart”) in connection with a new issue of shares with pre-emption rights…

  • Equity Capital Markets and Public M&A
  • Mergers & Acquisitions
  • Life Sciences

Så fungerar vårdens prioriteringar under Covid-19

Cirios webbinarium från den 29 april med Per Hedman och Odd Swarting – experter inom Life Sciences. Webbinariet behandlar vårdens…

  • Life Sciences

Cirio strengthens life science practice

Cirio announces that Odd Swarting has been recruited as Senior Counsel. The hire strengthens the firm’s client offerings in pharmaceutical…

  • Life Science, Healthcare & Food

Cirio advises Annexin in connection with its rights issue

Cirio Advokatbyrå AB advises Annexin Pharmaceuticals AB (publ), listed on Nasdaq First North Growth Market, in connection with its rights…

  • Life Sciences
  • Life Science, Healthcare & Food

Breakfast seminar coming up 7/3 – Cancer immunotherapy

The 2018 Nobel prize, leading Swedish research today and impacts on patients tomorrows. Cancer is the world’s second largest cause…

  • Life Sciences
  • Life Science, Healthcare & Food